Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
Fiche publication
Date publication
novembre 2014
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BEDENNE Laurent, Pr BOUCHE Olivier
Tous les auteurs :
Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, André T, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Boucher E, Rebischung C, Hammel P, Rougier P, Bedenne L, Bouché O
Lien Pubmed
Résumé
To compare epirubicin, cisplatin, and capecitabine (ECX) with fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatments in patients with advanced gastric or esophagogastric junction (EGJ) adenocarcinoma.
Mots clés
Adenocarcinoma, drug therapy, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, Camptothecin, administration & dosage, Capecitabine, Cisplatin, administration & dosage, Deoxycytidine, administration & dosage, Epirubicin, administration & dosage, Esophagogastric Junction, pathology, Female, Fluorouracil, administration & dosage, Follow-Up Studies, France, Humans, Leucovorin, administration & dosage, Male, Middle Aged, Prospective Studies, Quality of Life, Stomach Neoplasms, drug therapy, Survival Analysis, Treatment Outcome
Référence
J. Clin. Oncol.. 2014 Nov;32(31):3520-6